Endotracheal Tubes to Prevent Ventilator-Associated Pneumonia (PreVent2)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03705286|
Recruitment Status : Recruiting
First Posted : October 15, 2018
Last Update Posted : November 19, 2020
Researchers are looking at two different types of breathing tubes to see if one is better than the other at preventing pneumonia. One of the tubes has a design features to prevent leakage of fluids from the mouth and the back of the throat into the lower airways and lungs. This is important since leakage of small amounts of fluid into the lungs may lead to pneumonia. The other tube is the standard tube used at most hospitals.
The hypothesis is that the use of a breathing tube that reduces fluid leakage into the lungs will reduce the risk of developing pneumonia and improve quality of life and cognitive function, compared to the standard tube. The study will also look at the safety of the modified breathing tube, compared to the standard tube.
|Condition or disease||Intervention/treatment||Phase|
|Ventilator-acquired Pneumonia||Device: EVAC-PU-ETT Device: PVC-ETT||Not Applicable|
The proposed study will be a randomized, controlled trial, conducted under Exception From Informed Consent (EFIC), comparing patients who undergo emergency tracheal intubation with one of two different endotracheal tubes (ETTs), one of which is designed to prevent ventilator-associated pneumonia (VAP): 1) An ETT fitted with a lumen to allow continuous aspiration of subglottic secretions and made with a polyurethane cuff (EVAC-PU-ETT); and 2) A standard ETT with a polyvinylchloride cuff (PVC-ETT). Approximately 1,074 adult patients requiring endotracheal intubation in the ED or hospital for acute respiratory distress or failure will be randomly assigned in an equal fashion to be intubated with one of the two ETTs (537 patients in each group). Because endotracheal intubation is performed in an emergency setting, the unit of randomization will be the intubation kits containing, in a concealed manner, one of the two types of ETT. The intubation kits are placed in areas where emergency intubation teams receive their intubation equipment supplies, primarily in the ICUs and in the emergency department. The study is designed to allow all patients requiring emergency intubation to be potentially eligible for enrollment to ensure the applicability of the study findings to a generalizable setting of patients receiving emergency intubation outside the operating room.
The trial primary aim is to determine if EVAC-PU-ETT is as safe as PVC-ETT and if long-term patient quality of life and cognitive function are better in PU-CASS-ETT, compared with PVC-ETT. The investigators will also monitor any device-related adverse events. Additional secondary endpoints include the incidence of infection-related ventilator associated conditions (IVAC) and ventilator associated events (VAEs), as defined by the Center for Disease Control, respiratory antibiotics use, incidence of "clinical" VAP, 28-day ventilator-free days, mean daily Sequential Organ Failure Assessment (SOFA) score, length of ICU and hospital stay, and mortality up to six months will serve to evaluate other clinical meaningful consequences resulting from the occurrence of VAP. Furthermore, the study will perform economic evaluation (cost-consequence approach) of quality of life, healthcare resource utilization and cost for hospitals. Primary and secondary endpoints will be compared between the PU-CASS-ETT and PVC-ETT groups, using an intention-to-treat approach.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||1074 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Outcomes Assessor)|
|Official Title:||Randomized Trial of Endotracheal Tubes to Prevent Ventilator-Associated Pneumonia - PreVent 2 Study|
|Actual Study Start Date :||May 6, 2019|
|Estimated Primary Completion Date :||October 2022|
|Estimated Study Completion Date :||June 2023|
Active Comparator: PVC-ETT
Polyvinylchloride endotracheal tube
Placement of a EVAC-PU-ETT in the setting of emergent intubation.
Other Name: Shiley™ Evac Oral Tracheal Tube, SealGuard™, Murphy Eye
Continuous aspiration of subglottic secretions with polyurethane cuff endotracheal tube
Placement of a PVC-ETT in the setting of emergent intubation.
Other Name: Shiley™ Cuffed Basic Endotracheal Tube
- Quality of life [ Time Frame: 6 months ]36-item Short-Form General Health Survey (Scores range from 0 - 100; Lower scores = more disability, higher scores = less disability)
- Cognitive function [ Time Frame: 6 months ]Proportion of patients cognitively impaired, assessed by the National Alzheimer Coordinating Center's Uniform Data Set
- Airway related complications [ Time Frame: 6 months ]Device-related adverse events
- Infection Related Ventilator-Associated Complications (IVACs) [ Time Frame: Up to 28 days ]Center for Disease Control defined IVACs
- Ventilator-Associated Events (VAEs) [ Time Frame: Up to 28 days ]Center for Disease Control defined VAEs
- Healthcare costs [ Time Frame: 6 months ]Healthcare resource utilization
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03705286
|Contact: Miriam M Treggiari, MD, PhD, MPHemail@example.com|
|Contact: Michael Kamppfirstname.lastname@example.org|
|United States, Connecticut|
|Yale New Haven Hospital||Recruiting|
|New Haven, Connecticut, United States, 06511|
|Contact: Miriam Treggiari, MD email@example.com|
|Contact: Michael Kampp|
|Principal Investigator:||Miriam M Treggiari, MD, PhD, MPH||Yale University|